A Critical Test for FDA's Critical Path Initiative

FDA wants to reverse the deline in NDA approvals; the agency may have a key ally at a new center in Arizona.

By Cole Werble

The critical path for FDA’s effort to improve the drug development processruns through Tucson, Arizona.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Agency Leadership

More from Pink Sheet